AstraZeneca divests global rights to Movantik

25 February 2020 07:00 GMT

License to RedHill Biopharma supports AstraZeneca’s focus on main therapy areas

AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC).

Ruud Dobber, Executive Vice President, BioPharmaceuticals Business Unit, said: “This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope to enable reinvestment in our main therapy areas. Movantik2020欧洲杯体育足球滚球比分 is an important established medicine and the divestment to RedHill will ensure its continued availability for patients.”

As part of the agreement, AstraZeneca will continue to manufacture and supply Movantik to RedHill during a transition period. In 2015, AstraZeneca entered into a co-commercialisation agreement with Daiichi Sankyo, Inc. for Movantik in the US, which will be transferred to RedHill.

Financial considerations

RedHill will make an upfront payment of $52.5m to AstraZeneca on closing and a further non-contingent payment of $15m in 2021. Income arising from the upfront payment, offset by a charge for derecognition of the associated intangible asset, and the future payment will be reported in AstraZeneca’s financial statements within Other Operating Income & Expense. In 2019, Movantik 2020欧洲杯体育足球滚球比分generated sales of $96m in the US. The divestment is expected to complete in the first quarter of 2020, subject to customary closing conditions and regulatory clearances. Upon completion, the agreement will not impact the Company’s financial guidance for 2020.


Movantik is a once-daily oral PAMORA approved by the US Food and Drug Administration for the treatment of OIC in adult patients with chronic non-cancer pain. Movantik was licensed from Nektar Therapeutics in 2009. It was developed using Nektar’s oral small-molecule polymer conjugate technology. In 2016, AstraZeneca divested the rights in Europe to ProStrakan Group (now KKI) and the rights in Canada and Israel to Knight Therapeutics.


AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit and follow the Company on Twitter @.



Media Relations



Gonzalo Viña


2020欧洲杯体育足球滚球比分+44 203 749 5916

2020欧洲杯体育足球滚球比分Rob Skelding


2020欧洲杯体育足球滚球比分+44 203 749 5821

Rebecca Einhorn


+1 301 518 4122

Matt Kent


+44 203 749 5906

2020欧洲杯体育足球滚球比分Angela Fiorin


2020欧洲杯体育足球滚球比分+44 1223 344 690

2020欧洲杯体育足球滚球比分Jennifer Hursit


2020欧洲杯体育足球滚球比分+44 203 749 5762

Christina Malmberg Hägerstrand


+46 8 552 53 106

Michele Meixell


2020欧洲杯体育足球滚球比分+1 302 885 2677


Investor Relations



Thomas Kudsk Larsen


2020欧洲杯体育足球滚球比分+44 203 749 5712

Henry Wheeler


+44 203 749 5797

2020欧洲杯体育足球滚球比分Christer Gruvris


(Cardiovascular, Metabolism)

2020欧洲杯体育足球滚球比分+44 203 749 5711

Nick Stone

2020欧洲杯体育足球滚球比分BioPharmaceuticals (Renal) Environmental, Social and Governance

+44 203 749 5716

2020欧洲杯体育足球滚球比分Josie Afolabi

2020欧洲杯体育足球滚球比分BioPharmaceuticals (Respiratory)

+44 203 749 5631

Tom Waldron

Other medicines

+44 7385 033 717

Craig Marks


2020欧洲杯体育足球滚球比分Fixed income

2020欧洲杯体育足球滚球比分+44 7881 615 764

Jennifer Kretzmann

2020欧洲杯体育足球滚球比分Corporate access

2020欧洲杯体育足球滚球比分Retail investors

+44 203 749 5824

US toll-free


2020欧洲杯体育足球滚球比分+1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC



  • Corporate and financial
  • Partnering